NCT01714310View on ClinicalTrials.gov

Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Severe Mood Dysregulation
Interventions
DRUG

lisdexamfetamine

Titration and open label treatment from baseline visit for 12 week study.

DRUG

Placebo

Initiated at end of study week 4 and continued to study week 12.

DRUG

fluoxetine

Initiated at end of study week 4 and continued to study week 12.

Trial Locations (1)

90095

UCLA Semel Institute, Los Angeles

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Shire

INDUSTRY

lead

University of California, Los Angeles

OTHER